Efficacy and Safety of GV 550 in Acute Adenovirus Keratoconjunctivitis (Phase II Pilot Study, Multicentre, International, Randomised, Double-masked, Placebo-controlled, 2x40 Patients).

Trial Profile

Efficacy and Safety of GV 550 in Acute Adenovirus Keratoconjunctivitis (Phase II Pilot Study, Multicentre, International, Randomised, Double-masked, Placebo-controlled, 2x40 Patients).

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Feb 2013

At a glance

  • Drugs Ganciclovir (Primary)
  • Indications Keratoconjunctivitis
  • Focus Therapeutic Use
  • Sponsors Laboratoires Thea
  • Most Recent Events

    • 28 Apr 2012 Additional trial location (Germany) identified as reported by European Clinical Trials Database.
    • 28 Apr 2012 Planned number of patients changed to 80 as reported by European Clinical Trials Database.
    • 28 Apr 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2007-002455-16).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top